As of 2026, the FDA has declared national shortage designations for semaglutide and tirzepatide injection products resolved, which affects the regulatory basis under which compounding was previously more widely available
The result is a product category that looks like pharmaceutical innovation but is actually search-engine optimization wrapped in an adhesive bandage
Nasal delivery may be particularly effective in the treatment of neurological diseases due to the direct nose-to-brain pathway
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
Patient, government programs and insurance companies cranked up their spending on GLP-1s from 2018 to 2023 by more than 500%, from $13.7 billion to $71.7 billion, according to a study from the American Medical Association and the Centers for Disease Control and Prevention
I was trying to be proactive